Free Trial
NASDAQ:TRVN

Trevena (TRVN) Stock Price, News & Analysis

Trevena logo
$0.0005 0.00 (0.00%)
As of 11/13/2026 03:42 PM Eastern

About Trevena Stock (NASDAQ:TRVN)

Advanced

Key Stats

Today's Range
$0.0005
▼
$0.0005
50-Day Range
$0.00
▼
$0.07
52-Week Range
$0.00
▼
$1.50
Volume
977 shs
Average Volume
776 shs
Market Capitalization
$479.50
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Trevena, Inc. is a biopharmaceutical company focused on developing medicines for the treatment of acute and chronic pain, as well as disorders of the central nervous system. The company’s research has centered on G protein–coupled receptors and its “biased ligand” drug-discovery platform, which is intended to produce therapeutic effects while potentially reducing certain side effects associated with conventional treatments.

Trevena’s principal commercial product is OLINVYK (oliceridine) injection, an opioid analgesic approved by the U.S. Food and Drug Administration in 2020 for the management of acute pain severe enough to require an intravenous opioid analgesic in adults. The product was developed for use in hospital and other medically supervised settings. Trevena has also investigated additional candidates, including oral and injectable therapies designed to address pain and central nervous system conditions.

Founded in 2007 and headquartered in Chesterbrook, Pennsylvania, Trevena has historically operated primarily as a U.S.-based biotechnology company, with its lead product regulated and marketed in the United States. The company has undergone strategic and operational changes as it evaluated commercialization and development priorities. Its leadership has included biotechnology executive Carrie B. Jones, M.D., M.B.A., who served as president and chief executive officer during a period of the company’s commercial development.

AI Generated. May Contain Errors.

Receive TRVN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Trevena and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

TRVN Stock News Headlines

Trevena Inc.
The warning signs most investors see too late
Dr. Martin D. Weiss has publicly predicted six major American crashes since founding Weiss Ratings in 1971. Now, after 55 years of market analysis, he says conditions are forming for a financial crisis that could rival or exceed 2008.tc pixel
Trevena, Inc. (TRVN) - Yahoo Finance
JMP Securities downgrades Trevena (TRVN) to a Hold
See More Headlines

TRVN Stock Analysis - Frequently Asked Questions

Trevena's stock was trading at $0.0120 on January 1st, 2026. Since then, TRVN shares have decreased by 95.8% and is now trading at $0.0005.

Trevena, Inc. (NASDAQ:TRVN) issued its quarterly earnings data on Thursday, August, 8th. The biopharmaceutical company reported ($0.23) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($9.25) by $9.02. The biopharmaceutical company earned $330 thousand during the quarter.

Trevena shares reverse split on the morning of Tuesday, August 13th 2024.The 1-25 reverse split was announced on Thursday, August 8th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Monday, August 12th 2024. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split.

Shares of TRVN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Trevena investors own include Sorrento Therapeutics (SRNE), Novavax (NVAX), NIO (NIO), Inovio Pharmaceuticals (INO), Advanced Micro Devices (AMD), Micron Technology (MU) and SCYNEXIS (SCYX).

Company Calendar

Today
11/16/2026
Next Earnings (Estimated)
11/16/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceuticals
Sub-Industry
Pharmaceuticals
Current Symbol
NASDAQ:TRVN
CIK
1429560
Fax
N/A
Employees
23
Year Founded
2008

Profitability

EPS (Trailing Twelve Months)
($47.04)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$40.29 million
Net Margins
N/A
Pretax Margin
-6,222.30%
Return on Equity
N/A
Return on Assets
-119.55%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
2.42
Quick Ratio
2.42

Sales & Book Value

Annual Sales
$443 thousand
Price / Sales
0.00
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
($11.07) per share
Price / Book
0.00

Miscellaneous

Outstanding Shares
959,000
Free Float
841,000
Market Cap
$479.50
Optionable
No Data
Beta
-1.83

Social Links

7 Stocks That Could Lead the Next Market Boom Cover

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

This page (NASDAQ:TRVN) was last updated on 11/13/2026 by MarketBeat.com Staff.
From Our Partners